HomeInsightsPE

Laurus Labs Ltd P/E Ratio

Laurus Labs Ltd P/E Ratio

download
stocks purchased

₹ 1.0 Cr

Volume transacted

stocks purchased

22.2 K

stocks traded

Last Updated time: 22 Jul 9.00 AM

Image

Laurus Labs Ltd

NSE: LAURUSLABS

PE

147.4

Last updated : 22 Jul 9.00 AM

Key Highlights

    The P/E Ratio of Laurus Labs Ltd is 147.4 as of 22 Jul 9.00 AM .a1#The P/E Ratio of Laurus Labs Ltd changed from 45.4 on March 2019 to 131.5 on March 2024 . This represents a CAGR of 19.39% over 6 years. a1#The Latest Trading Price of Laurus Labs Ltd is ₹ 442.15 as of 22 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.5 to 27.6 in 5 years. This represents a CAGR of -0.64%a1# The PE Ratio of Automobile industry is 18.5. The PE Ratio of Finance industry is 23.8. The PE Ratio of IT - Software industry is 29.3. The PE Ratio of Pharmaceuticals industry is 38.8. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 20.4. In 2024a1#The Market Cap of Laurus Labs Ltd changed from ₹ 4254 crore on March 2019 to ₹ 21113 crore on March 2024 . This represents a CAGR of 30.60% over 6 years. a1#The Revenue of Laurus Labs Ltd changed from ₹ 1540 crore to ₹ 1458 crore over 8 quarters. This represents a CAGR of -2.71% a1#The EBITDA of Laurus Labs Ltd changed from ₹ 455.92 crore to ₹ 260.02 crore over 8 quarters. This represents a CAGR of -24.48% a1#The Net Pr of Laurus Labs Ltd changed from ₹ 252.54 crore to ₹ 75.32 crore over 8 quarters. This represents a CAGR of -45.39% a1#The Dividend Payout of Laurus Labs Ltd changed from 16.81 % on March 2019 to 19.27 % on March 2024 . This represents a CAGR of 2.30% over 6 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of Laurus Labs Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of Laurus Labs Ltd

Period
Mar '1945.4
Mar '2013.5
Mar '2119.8
Mar '2238.3
Mar '2320
Mar '24131.5

Company Fundamentals for Laurus Labs Ltd

Market Cap

23,838 Cr

EPS

3.0

P/E Ratio (TTM) *

147.4

P/B Ratio (TTM) *

5.8

Day’s High

452.0

Day’s Low

436.95

DTE *

0.6

ROE *

3.9

52 Week High

484.95

52 Week Low

328.15

ROCE *

6.1

* All values are consolidated

Last Updated time: 22 Jul 9.00 AM

* All values are consolidated

Last Updated time: 22 Jul 9.00 AM

Image

Laurus Labs Ltd

NSE: LAURUSLABS

PRICE

442.15

2.00 (0.45%)

stock direction

Last updated : 22 Jul 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Laurus Labs Ltd

Strength

6

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Laurus Labs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Laurus Labs Ltd

Market Value

23,839

Asset Value

3,921

5.1 X

Value addition

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Laurus Labs Ltd14723,838
Sun Pharmaceuticals Industries Ltd38380,990
Divis Laboratories Ltd75120,383
Cipla Ltd28120,296
Zydus Lifesciences Ltd30116,160
Dr Reddys Laboratories Ltd20112,931

Key Valuation Metric of Laurus Labs Ltd

Earnings

160 Cr

147.4 X

PE Ratio

Market Cap

₹23838Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

160 Cr

147.4 X

PE Ratio

Market Cap

₹23838Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of Laurus Labs Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Laurus Labs Ltd

Period
Mar '194255
Mar '203449
Mar '2119428
Mar '2231707
Mar '2315782
Mar '2421114

* All values are a in crore

×

Historical Revenue of Laurus Labs Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Laurus Labs Ltd

Period
Jun '221541
Sep '221577
Dec '221546
Mar '231383
Jun '231185
Sep '231226
Dec '231197
Mar '241458

* All values are a in crore

×

Historical EBITDA of Laurus Labs Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Laurus Labs Ltd

Period
Jun '22456
Sep '22450
Dec '22405
Mar '23287
Jun '23170
Sep '23190
Dec '23184
Mar '24260

* All values are a in crore

×

Historical Net Profit of Laurus Labs Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Laurus Labs Ltd

Period
Jun '22253
Sep '22234
Dec '22203
Mar '23107
Jun '2328
Sep '2339
Dec '2325
Mar '2475

* All values are a in crore

×

Historical Dividend Payout of Laurus Labs Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Laurus Labs Ltd

Period
Mar '1917
Mar '2010
Mar '2111
Mar '2214
Mar '2314
Mar '2419

* All values are a in %

About Laurus Labs Ltd

About Laurus Labs Ltd

    Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology. The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (PPIs) amongst others. The company currently operates 4 manufacturing facilities in Visakhapatnam, Andhra Pradesh. Three of these facilities manufacture APIs and ingredients, while the fourth facility produces Finished Dosage Formulations (FDFs) and one API. The company's strategic and early investments in R&D and manufacturing infrastructure has enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing 'donor-funded access-to-medicines markets' of Sub-Saharan Africa, South-East Asia and Latin America. The company also has growing synthesis and nutraceutical/ cosmeceutical ingredients businesses. Further, it is increasingly focused towards growing its integrated generics finished dosage forms ('FDFs') business in which it has made significant investments. Laurus Labs operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis and Ingredients. Its Generics - API business comprises the development, manufacture and sale of APIs and advanced intermediates; itsGenerics - FDF business comprises the development and manufacture of oral solid formulations; its Synthesis business includes contract development and manufacturing services for global pharmaceutical companies; and its ingredients business comprises the manufacture and sale of specialty ingredients for use in the nutraceutical and cosmeceutical sectors. The company has launched 59 products since its inception in 2005. Its key customers include Aspen Pharmacare Limited, Aurobindo Pharma Limited, Cipla Limited, Mylan Laboratories Limited, NATCO Pharma Limited ('NATCO') and Strides Shasun Limited. As of September 30, 2016, the Company owned 34 patents and had 152 pending patent applications, in several countries. Laurus Labs Limited was originally incorporated as 'Laurus Labs Private Limited' on September 19, 2005 at Hyderabad, Andhra Pradesh, India as a private limited company. The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited on February 12, 2007. Subsequently the name of the company was changed to Aptuit Laurus Limited consequent to the strategic partnership entered into by the company with Aptuit Singapore on July 19, 2007. Thereafter the company was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited on July 24, 2007. Subsequently the name of the company was changed to Laurus Labs Private Limited consequent to the proposed dilution of the shareholding of Aptuit Singapore in the Company on February 21, 2012. Further, the company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited on August 16, 2016. The company disinvested its 100% stake in Viziphar Biosciences Private Limited vide Agreement dated April 18, 2016, being the effective date of Agreement as April 1, 2016 and therefore Viziphar Biosciences Private Limited ceased to be the Subsidiary of the Company w.e.f. April 1, 2016. Its dedicated manufacturing facility for Aspen was inaugurated and became operational from November 2016. The company acquired balance 73% of equity shareholding of its Associate Company, namely Sriam Labs Private Limited with effect from November 1, 2016, thereby Sriam Labs Private Limited became 2nd 100% wholly Owned Subsidiary of the Company. Sriam Labs Private Limited is a private limited company based in India and engaged in design, development and manufacture of Active pharmaceutical intermediates and Intermediates to cater to the needs of pharmaceutical industry, in exchange for cash. The Group acquired Sriam Labs Private Limited because it will help realize the anticipated growth opportunities and synergies from combining these businesses. During the year ended 31 March 2017, the company expanded its R&D Centre at Hyderabad. It initiated ARV API supply into the European market. USFDA and WHO-Geneva Inspections at the company's Unit-2 was completed. It signed a contract with Dr. Reddy's Lab for the development and marketing of several anti-retroviral formulations on profit and cost sharing basis. Under Profit sharing arrangement between Laurus Labs and Natco for Hepatitis-C Segment, Natco launched Velpatasvir and Sofosbuvir combination in Nepal and launched in India in May 2017. During the year ended 31 March 2017, Laurus Labs signed manufacturing and supply agreement for Oncology NCE for clinical phase and commercial supplies. During the year under review, the company filed 3 ANDAs with USFDA and one dossier with WHO-Geneva. During the year 2019, the Company commenced commercial operations from Unit 4 and Unit 5. During the year 2019, the company incorporated a step down subsidiary in Germany. During the year 2019, the company's Unit 6 USFDA inspection was completed successfully with one observation. In FY19, Company launched Tenofovir, Metformin in US, Tenofovir in Canada, DLT (a three-product combination product) in LMIC countries under partnership with Global Fund for treatment of HIV/AIDS. Also, it commenced supply to Europe under contract manufacturing. In FY 2020, the Company launched Hydroxychloroquine in the United States. It completed backward integration in gemcitabine oncology API. It initiated TLD supplies for the Global Fund tender. During the year 2021, Company acquired a 72.55% stake in Richcore Lifesciences from two private equity funds, Eight Roads and Ventureast and became its subsidiary. It launched TLE400 in the LMIC market. It partnered with a leading generic player in the EU region for contract manufacturing opportunities. It commenced marketing of in-licensed products. It participated with global fund tenders such as PEPFAR, WHO and various African in-country tenders. It completed four drug product validations, apart from the filing of 27 ANDAs and NDAs. It began construction of large formulation manufacturing block which will be available for commercial use starting Q3 2021. It started 3 new manufacturing blocks for commercial manufacturing of intermediates and APIs. It created additional formulation capacity by de-bottlenecking operations. It acquired a company in South Africa and renamed it as Laurus Generics (SA) Pty Ltd. to cater to the needs to South African Market. It has purchased 18 acres of land in Hyderabad to set up a greenfield Finished Dosage Forms Unit. During the year 2021, Company's wholly-owned subsidiary i.e, Laurus Synthesis Inc., USA merged into Laurus Generics Inc., USA, which was a step down subsidiary of the Company. During the year 2022, Company acquired 26.62% of stake in Immunoadoptive Cell Therapy Private Limited, with around Rs. 46 crore investment. During the period 2021-22, Laurus Ingredients Private Limited, a step down subsidiary of the Company was voluntarily strike off from the Regsiter of Companies. It infused more capital into Laurus Generics Inc., due to increase in operations, to a tune of USD 2 Millions. During the year 2022, it commissioned 1 billion tablets capacity. It signed an agreement with MPP (Medicine Patient Pool) to manufacture Molnupiravir, oral COVID-19 antiviral medication. It acquired lands for two API manufacturing units in Visakhapatnam and one land parcel in Hyderabad for further expansion and its 100% subsidiary, LSPL has acquired two land parcels for manufacturing in Visakhapatnam and one land parcel for its R&D facility in Hyderabad. During 2022-23, the Company incorporated Laurus Speciality Chemicals Pvt. Ltd., a Wholly Owned subsidiary of Laurus Synthesis Pvt. Ltd. for Specialty Chemicals Business on December 01, 2022. It acquired 26% Stake in Ethan Energy. It commissioned the Unit-2 operation project.

Laurus Labs Ltd News Hub

News

Laurus Labs to discuss results

Laurus Labs will hold a meeting of the Board of Directors of the Company on 25 July 2024. ...

Read more

22 Jul 202410:34

News

Volumes spurt at Laurus Labs Ltd counter

K E C International Ltd, Network 18 Media & Investments Ltd, Castrol India Ltd, Sheela Foa...

Read more

03 Jul 202411:00

News

Laurus Labs Ltd up for third consecutive session

Laurus Labs Ltd is up for a third straight session today. The stock is quoting at Rs 435.4...

Read more

02 Jul 202413:05

News

Laurus Lab receives affirmation in ratings for bank facilities

Laurus Lab announced that CARE has reaffirmed the long term rating on company's bank facil...

Read more

18 Jun 202413:53

News

Laurus Labs edges lower after CARE Ratings downgrades rating outlook to 'negative'

The credit rating agency has affirmed its rating on the short-term credit facilities of La...

Read more

18 Jun 202415:20

News

Laurus Labs Ltd spurts 0.12%, gains for fifth straight session

Laurus Labs Ltd is up for a fifth straight session today. The stock is quoting at Rs 444.2...

Read more

11 Jun 202413:00

Product Composition by Percentage (Revenue)

FAQs for PE of Laurus Labs Ltd

What is Laurus Labs Ltd current share price?

The current market price of Laurus Labs Ltd as of July 22, 2024 is ₹442.15.

Is Laurus Labs Ltd a good investment?

As per BlinkX Score Laurus Labs Ltd scores 82 in Revenue, 83 in Profitability. However it's advisable to conduct comprehensive research or seek advice from experts to evaluate whether it aligns with your investment objectives.

What are Laurus Labs Ltd's total net assets?

According to Laurus Labs Ltd's most recent financial filings, the company's net assets total ₹3920.9 Cr.

Is Laurus Labs Ltd making a profit or loss?

Laurus Labs Ltd's net Profit as of July 22, 2024 is close to ₹160 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199